List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Overview
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Companies Involved in Therapeutics Development
Accendatech Co Ltd
Astellas Pharma Inc
Beam Therapeutics Inc
Jazz Pharmaceuticals Plc
MDI Therapeutics Inc
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Drug Profiles
ACT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-3288802 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bi-specific Antibody to Inhibit TAFI and PAI-1 for Thrombosis and Stroke - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
defibrotide sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate SERPINA1 for Alpha-1 Antitrypsin Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDI-2268 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDI-2517 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SK-216 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-5275 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-5441 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-5484 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-5614 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Dormant Products
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Discontinued Products
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Product Development Milestones
Featured News & Press Releases
May 20, 2021: Jazz to present new data on Defitelio at EHA2021
Nov 13, 2020: Beam Therapeutics presents first data highlighting Base Editing Program for Alpha-1 Antitrypsin Deficiency at AASLD
Jul 31, 2020: Clinigen receives regulatory approval for Defitelio (Defibrotide) in Australia
May 14, 2020: Jazz Pharmaceuticals announces presentation on Defitelio at Virtual EHA 2020 Meeting
Apr 29, 2020: Jazz Pharmaceuticals stops enrollment in phase 3 study evaluating Defibrotide for the prevention of Veno-Occlusive Disease
Apr 28, 2020: Beam Therapeutics to present first data highlighting base editing program for alpha-1 antitrypsin deficiency at 23rd ASGCT Annual Meeting
Nov 07, 2019: Jazz Pharmaceuticals to present abstracts on Defitelio (defibrotide sodium) at ASH 2019 Annual Meeting
Oct 10, 2019: Jazz Pharmaceuticals announces first patient enrolled in phase 2 clinical trial evaluating defibrotide for the prevention of CAR-T Associated Neurotoxicity
Sep 04, 2019: Launch of Defitelio injection 200mg for the treatment of sinusoidal obstruction syndrome (hepatic veno-occlusive disease)
Jun 18, 2019: Marketing approval of Defitelio by MHLW for the treatment of sinusoidal obstruction syndrome / hepatic veno-occlusive disease
May 16, 2019: Jazz Pharmaceuticals to present new data on defitelio at upcoming EHA Congress
Mar 25, 2019: Experimental drug reverses high cholesterol, obesity-related nonalcoholic fatty liver disease in animals
Nov 28, 2018: Jazz Pharmaceuticals to present data on Defitelio at ASH 2018 Annual Meeting
Oct 17, 2018: New Drug Application Filed for defibrotide sodium
Sep 19, 2018: Nippon Shinyaku announces orphan drug designation granted to NS-73
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Accendatech Co Ltd, 2021
Pipeline by Astellas Pharma Inc, 2021
Pipeline by Beam Therapeutics Inc, 2021
Pipeline by Jazz Pharmaceuticals Plc, 2021
Pipeline by MDI Therapeutics Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Discontinued Products, 2021

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

Companies Mentioned
• Accendatech Co Ltd
• Astellas Pharma Inc
• Beam Therapeutics Inc
• Jazz Pharmaceuticals Plc
• MDI Therapeutics Inc